Arrowhead Research (ARWR) PT Slashed to $2 at Jefferies

November 30, 2016 8:12 AM EST
Get Alerts ARWR Hot Sheet
Price: $1.84 -6.12%

Rating Summary:
    1 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade ARWR Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst Eun Yang lowered his price target on Arrowhead Research (NASDAQ: ARWR) to $2.00 (from $5.00) while maintaining a Hold rating after the company discontinues its EX1-based clinical programs (ARC-520, ARC-521, ARC-AAT) given likely "substantial" delays due to need for add'l non-clinical studies due to EX1 dose-related toxicity; and focuses on SC/extra-hepatic pipeline to better align its resources.

"This is surprising given that on 11/8/16, ARWR noted a clinical hold on one of ARC-520 programs would not affect other programs," Yang notes.

The $2 PT comes on cash & AMGN collaboration.

For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.

Shares of Arrowhead Research closed at $4.39 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment